Compare Moderna, Inc. (MRNA) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wheaton Precious Metals Corp — how do they compare? Moderna, Inc. trades at $225.06 (market cap $78.65B), while Wheaton Precious Metals Corp trades at $138.54 (market cap $61.17B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Wheaton Precious Metals Corp for 66 Days on average.
| MRNA | WPM | |
|---|---|---|
Market Cap | $78.65B | $61.17B |
Volume | 37,373,437 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $203.46 | $165.72 |
52-Week Low | $22.36 | $94.37 |
Typical Hold Time | 59 Days | 66 Days |
Enterprise Value | $74.80B | $63.05B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Wheaton Precious Metals (WPM) trades at $138.1, up 3.3% today, with a bearish technical signal despite recent earnings beats. The company reported record 2025 revenue of $2.31B and net income of $1.47B, supported by strong margins. Analyst consensus is bullish with an 80% buy rating and a $164.80 price target, while news highlights growth ambitions targeting 1.2M ounces by 2030.
WPM offers exposure to gold and silver streaming with robust profitability, but faces risks from gold price volatility and high valuations. The stock's upside hinges on execution of its funded growth pipeline, though technical indicators suggest near-term resistance near $138.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
